论文部分内容阅读
目的探究奥美拉唑联合雷贝拉唑治疗消化性溃疡疗效观察及安全性。方法回顾性选取2015年9月至2016年9月收治的125例消化性溃疡患者临床资料进行分析,将其分为对照组(60例)、研究组(65例),对照组予以奥美拉唑进行治疗,研究组予以雷贝拉唑与奥美拉唑联合治疗,观察两组炎性因子变化情况以及不良反应发生状况。结果研究组炎性因子各项水平均显著低于对照组(P<0.05),研究组总不良反应3.07%与对照组8.33%相比无显著差异(P>0.05)。结论消化性溃疡患者应用奥美拉唑与雷贝拉唑进行联合治疗可有效提高临床治疗效果,缓解患者临床症状及体征,从而提高生活质量。
Objective To investigate the efficacy and safety of omeprazole and rabeprazole in the treatment of peptic ulcer. Methods The clinical data of 125 patients with peptic ulcer admitted from September 2015 to September 2016 were retrospectively analyzed. They were divided into control group (60 cases), study group (65 cases) and control group Azole treatment, the study group to rabeprazole and omeprazole combination therapy, changes in the two groups of inflammatory cytokines and adverse reactions were observed. Results The levels of inflammatory cytokines in the study group were significantly lower than those in the control group (P <0.05). There was no significant difference in the total adverse reaction (3.07%) between the study group and the control group (8.33%) (P> 0.05). Conclusions The combination of omeprazole and rabeprazole in patients with peptic ulcer can effectively improve the clinical effect, alleviate the clinical symptoms and signs of patients and improve the quality of life.